Biphosphonates are compounds that inhibit bone reabsorption mediated by osteoclasts or the progression of periodontal disease independent on the host response to pathogenic bacteria that colonize the tooth surface. The use of biphosphonates in oral implantology is still in the experimental stage. The aim of this study is to evaluate the efficacy of a non-aminobiphosphonate combined with a surfactant to increase the ability of the drug to link to the implant and bone surfaces in the development of osseointegration in rabbits. Smooth titanium implants were devised to be used on rabbit femurs. A topical administration of clodronate combined with the surfactant (Tween 20) at different concentrations was made on the implant surface and in the implant site to increase the bone and implant adhesiveness. Placebo was given to the control group. New Zealand rabbits were used and sacrificed by CO 2 after 8 weeks from the implantations. A histologic and histo-morphometric analysis was carried out. Results did not show significant difference between the tests and the placebo groups. Our data are different from other similar studies obtaining statistically significant differences. These differences could depend on the efficacy of the drug used and on the procedure of application of the drug on the implant. This study demonstrates poor efficacy of clodronate applied topically to the implant and implant site during .surgery to increase the percentage of osseointegration in the implant. Further studies using different fixation techniques of the drug may be necessary to confirm the present data.
Osseointegration is the direct contact between vital bone and the surface of the implant (l) and is influenced by many factors, such as anatomy of the edentular alveolar crest, the design of the implant, the volume, vascularization, and the mineral density of the bone (2). The percentage of success of bone implants in the maxilla with low bone quality is lower than in the mandible (3) . Biphosphonates in this context can be of great help since they can increase bone density (4) . Inflammation in these sites is produced by bacterial products that initiate a local host response that involves: generation of cytokines mostly produced by osteoblasts; recruitment of inflammatory cells; release of lytic enzymes; and activation of osteoclasts, which is strictly dependent from T lymphocyte. Biphosphonates are already considered the most suitable therapy for osteometabolic diseases (4) (5) (6) (7) (8) .
Biphosphonates have high affinity for mineralized bone and it is in this context that they show their biological functions (9) . These drugs act on bone homeostasis, inhibiting the reabsorption of bone mediated by osteoclasts. They inhibit the activity of mature osteoclasts (10) , increase the apoptosis processes of osteoclasts (11) , and inhibit the formation and recruitment of new osteoclasts (12) . TNF-related apoptosis-inducing ligand (TRAIL) is a cytotoxic protein inducing apoptosis, upon binding to death domain-containing receptors DR4 and DRS, its activity can be modulated by association with two membrane-bound decoy receptors, namely DcRl and DcR2, lacking functional death domains and conferring TRAIL resistance on expressing cells (13) (14) . TRAIL is expressed by many cells. Recent works demonstrated that OBs express TRAIL and its receptors, but in normal conditions they are not sensitive to its apoptotic effects. Interestingly, a recent finding showed that Staphylococcus Aureus induced TRAIL expression in osteoblasts (15) , leading to augmented osteoblast apoptosis with consequent bone destruction. Recent studies show that some of these compounds can stimulate the differentiation and the activity of osteoblasts (16) and have different and numerous extra-scheletal biological properties (17) . Aminobiphosponates have an anti-reabsortion property 10-100-10,000 times higher than the nonaminobiphosponates (Table I) (18) . Many published papers confirm that aminobiphosphonates increase the bone-implant contact percentage with respect to control groups (19) (20) (21) (22) .
It has been hypothesized that clodronate combined with Tween 20, a surfactant, is able to form a uniform and stable "liquid bridge", firmly and lastingly interposed between the bone and the implant surface, that could have the advantage of a greater length of time in situ before, during and after application of the implant (23) .
The aim of the present study is to evaluate the effects of local administration of a nonamino-biphosphonate (clodronate) combined with the surfactant Tween 20 on improving the osseointegration of titanium implants in an animal model.
MATERIALS AND METHODS
In these experiments 20 female New Zealand rabbits with an average weight of 3.8 Kg were used. Forty titanium implants with smooth surface, 2 mm diameter and 5 mm length, were positioned in the rabbit femurs on the right and left distal metaphysis. The clodronate used in this study, in collaboration with the Institute of Pharmacology of the University of Padova, Italy, was modified by adding Polyethylene glycol sorbitan monolaurate, a non-ionic surfactant, commercially known by the name Tween 20 (24) (Sigma, Saint Louis, Missouri, USA) at 3 different concentrations: 33%, 16.5% and 4% in IOO mg of clodronate.
Forty implants were placed in twenty rabbits: 4 groups of 5 rabbits each. Three test groups of 10 implants, 2 implants for each rabbit, one in the left and one in the right leg ( Fig. I) using the 3 different concentrations of the Tween 20. In addition, a control group of 10 implants received titanium implants with saline solution as placebo.
Experimental procedure
Surgical procedures were performed under general anaesthesia induced by a mixture of Ketamine Chlorhydrate (Ketavet, Gellini-Intervet, Milan, Italy) and Medetomidine Hydrochloride (l cc) (Domitor, Pfizer Inc., NY, USA). In each rabbit, a small incision was made on the right and left distal femoral metaphysis. After exposure of the bone, 1.5 mm holes were drilled. Implant sites were arranged with a low rotating speed (less than 800 rpm), under continuous irrigation with sterilized saline solution. After surgery all implants showed primary stability. At the end of the procedure tissues were sutured with a polyglycolic reabsorbable suture (Dexon II, Kendall Company, Massachusetts, USA).
The surgical sites were disinfected with IO% Povidone-iodine (Betadine, Asta Medica GmbH, Frankfurt, Germany) and the rabbits were given topical antibiotic therapy with Kanamycine Sulfate (Kana spray, Gellini-Intervet, Milan, Italy). Then for 5 days the animals received systemic antibiotic therapy using Enrofloxacin (l ml al 5%) (Enrofloxacin, I ml al 5% -Baytril, Bayer-Leverkusen, Germany). The animals were sacrificed in a CO 2 gas chamber after 8 weeks from surgery. This study protocol was approved by the Regional Ethics Committee for Laboratory Animal Research of the Catholic University Rome.
After retrieval the specimens were dehydrated and subsequently infiltrated in methacrylate resin from a starting solution 50% ethanol/resin and subsequently 100% resin, with each step lasting 24 h. Photopolymerization was obtained using a 48 h exposure to blue-light and the implants were oriented in order to visualize the two different sides at the same time. After polymerization, the plastic blocks were ground to remove the excess resin and to expose the implants and then were glued on plastic slides using a methacrylate-based glue.
A high speed rotating blade microtome (Micromet, Remet, Bologna, Italy) was used to separate the section from the block, thus obtaining a 250 micron thick section. The section was then ground down to about 40 microns using a grinding machine (LS-2, Remet, Bologna, Italy) equipped with waterproof grinding paper. After the grinding procedure was finished, each section was polished with a polishing paper and a 3-micron polishing cream. Toluidine-blue staining was used to analyze the different ages and re-modelling pattern of the bone, and basic-fuchsin was used to distinguish the fibrous tissue and to have a better contrast. The histomorphometric analysis was performed by digitizing the images from the microscope using a Color Video Camera ( JVC TK-C1380, Color Video Camera, IVC Victor Company, Japan) and a frame grabber.
The images were acquired with a lOX objective including the entire implant surface. Subsequently the digitized images were analyzed with image analysis software (lAS 2000, Delta Sistemi, Italy). For each implant the most central section was analyzed and the Bone-to-Implant Contact (B.LC.) was calculated on the samples obtained. Statistical analysis (ANOVA) was carried out for each sample; the percentage were calculated and expressed by considering the total length of the implant interface.
RESULTS
None of the animals died during the postoperative two-month period. No implant was rejected or expelled. A wound dehiscence was observed in two rabbits, and only one rabbit showed evidence of infection that was resolved by scrubbing the wound and antibiotic washings. The percent values ofB.I.C. that were calculated for the three test groups differed slightly compared to the control groups. In fact, in groups A and B the B.I.C. measured 45%, while in group C and in the control group it was about 41% (Table II ). An important result was the high value of the standard deviation in group B, representing dispersion of the samples in this group.
The differences that emerged from the test groups and the control group are not statistically significant, the p value being equal to 0.8737. This data was also confirmed in the histological images where the bone-implant contact sites were similar between the various groups. The cortical layer was restored around the implant even though a thickening of the cortical density was always present around the implants (Fig. 2 A, B) . The anti-reabsorptive strength ofetidronate is considered a reference standard. Amino biphosponates have an anti-reabsortion property higher than the nonaminobiphosponates.
All the implants were in direct contact with the surrounding bone in the cortical passage, even though the mean of mc percentage was different (Table II) . The newly-formed bone penetrated deeply into the implant threads and was also in contact with the deeper part of the threads (Fig. 2 C) . The bone contact on the implant surface was interrupted by small and thin marrow spaces containing fibroblasts, capillaries, osteoblasts, osteoclasts and macrophages ( Fig. 2 D, E) . No sign of osteoconductivity of the implant surface was evident, in that the bone stopped at the inner side of the cortical layer and did not slide along the implant surface into the central medullary canal (Fig. 2 A, B) .
The pattern ofthe new bone was of the composite type, made of a core of woven bone surrounded by lamellar bone arranged in an osteonic pattern (Fig. 2  C) . Some secondary osteons were also visible in this context, showing a history of remodeling process. Osteoid bands and osteoclast were found on the bone surfaces surrounding the implant. These cells show the remodeling processes were still present both at the interface and in the surrounding periimplant bone (Fig. 2 D) . Some debris of drilled bone embedded into the newly formed bone matrix was still visible (Fig. 2 C) . The osteonic arrangement around the implant was different compared to the normal arrangement of the cortical bone at a distance from it, even though the walls of the drilled hole were no longer visible (Fig. 2 F) . statistically significant differences were noticed between test groups and controls. Tanzer et al. (21) have demonstrated in dog ulnas that a solution of zolendronate applied by pipette directly onto the orthopaedic implant coated with hydroxyapatite, increased peri-implant bone tissue. Yoshinari et al. in 2001 (22) proposed a new technique to fix biphosphonates on titanium surfaces. According to these authors , coating the implant surface with thin layers of calcium phosphate resulted in a greater immobilization of the drug. The strong affinity of biphosphonates for calcium phosphate would explain this phenomenon.
In the year 2002 a new in vivo study (20) by the same authors evaluated bone response around implants coated with aminobiphosphonates. Four weeks after the implantation, higher percentage of bone contact was found around the thin Ca-Pcoated implants compared to that of the control group. After 12 weeks from implantation the highest percentage of bone contact was found around the bisphosphonate-immobilized implants.
These data suggest that a thin layer of calcium phosphate fixed to an amino-biphosphonate is effective in increasing bone-implant contact. The calcium phosphate coating is effective since it contributes to regulating the local action of biphosphonate and it has an elevated affinity for calcium ions conferred by the oxide group present in the lateral chain R I and chelates the Ca ion with Our data demonstrate that administration of modified clodronate used topically in an intraoperative setting did not determine an increase in the percentage of the contact area between bone and implant. These results differ from other studies (20) (21) (22) that used aminobiphosphonates where Fig. 2 
. A) Group A. A detail ofbone implant interface, (25x magnification). TCD: Thickening ofthe Cortical Density; B) Group C. No sign ofosteoconductivity of the implant surface was revealed, (25x magnification).; C) Group B. The newly formed bone penetrated into the implant threads also in contact with a deeper part ofthem. The pattern ofthe new bone was ofthe composite type, being made ofthe core ofwoven bone (WB) surrounded by lamellar bone arranged in an osteonic pattern (OP). Debris ofdrilled bone (DDB) embedded into the newly formed bone matrix was still visible. (50x magnification); D) Control Group. New bone arranged in osteonic pattern (OP). The bone contact on the implant surface was not continuous but was interruptedbysmall and thin marrow space (MS). Some secondary osteons were also visible in this context, showing a history ofremodeling process (R) andformation (F) (50x magnification). E) Group A.
Higher magnification ofthe implant interface, note the thin marrow space containing osteoblast and macrophages (200x magnification); F) Group C. Osteonic arrangement around the implant is different compared to the normal arrangement ofthe cortical bone at some distance from it (50x magnification). a triple bond (25) . In an in vivo study, Kajiwara et al. (19) have shown the efficacy of an aminobiphosphonate, pamidronate, fixed according to the Yoshinari technique, stimulating the formation of bone tissue around the implant inserted in rat tibias. The similar findings found in this study highlight the role played by biphosphonates in the process of periimplant osteogenesis.
The divergence found in the results of the present study, compared to similar studies, may depend on two important aspects: the efficacy of the drug used and the procedure of application of the drug on the implant surface. As for the drug, a non-amino biphosphonate was used, which is less effective than the amino-biphosphonates used in other similar studies. As previously mentioned, the non-amino-bisfosfonate clodronate has a theurapeutic effect 1O,000-fold lower than the amino-bisphosphonate (Table I) .
Concerning the modality of the drug application, washing or wetting the implant surface and site by the drug during the surgical procedure could be less effective than linkage techniques used in previously cited studies where the drug was fixed on the implant coating by more complex techniques.
In these last cases, the release of the bisphosphonate would occur over a long period despite the wellknown high bonding affinity of bisphosphonates to hydroxyapatite (22) . The importance of this aspect was analyzed by Tanzer et al. (21) , in a study published in 2005, who demonstrated that the release of the drug in the coated implants is more constant and lasts longer than in non-coated implants.
The results of this study demonstrate that clodronate in association with Tween 20 applied topically during the surgical procedure in the implant site and on the implant surface does not determine a percent increase of osteointegration. Further studies using different fixation techniques for the drug may be necessary to confirm the present data.
